Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
Novel therapies are needed for patients with newly diagnosed multiple myeloma (NDMM). Elotuzumab plus lenalidomide and dexamethasone (ELd) is approved for the treatment of relapsed/refractory multiple myeloma (RRMM). This phase 2 study in Japan evaluated ELd vs lenalidomide and dexamethasone (Ld) in patients with NDMM who were ineligible for stem cell transplantation. Elotuzumab infusion was accelerated to 5 mL/min by dose 3, cycle 1, allowing most subsequent infusions to be completed within 1 h. The primary endpoint was overall response rate (ORR) in the ELd arm. Secondary endpoints were the difference in ORR between treatments, and progression-free survival (PFS). Patients were randomized to ELd (n = 40) or Ld (n = 42); median number of treatment cycles was 13 (ELd) and 12 (Ld). In the ELd arm, ORR was 88% [70% confidence interval (CI) 80–93]. The estimated difference in ORR between treatments was 13% (95% CI − 4, 30) in favor of ELd. Progression-free survival data were immature. Safety was consistent with previous findings of ELd in Japanese patients with RRMM. No infusion reactions occurred at the maximum rate of 5 mL/min, which was used in 89% of elotuzumab infusions. ELd may be an effective, well-tolerated frontline treatment for patients with NDMM ineligible for stem cell transplantation.
KeywordsMultiple myeloma Newly diagnosed Elotuzumab Stem cell transplantation-ineligible
The study was funded by Bristol-Myers Squibb K.K. Under the direction of the authors, professional medical writing assistance in the form of writing the first draft, drafting figures and tables, and collating author comments was provided by Laura Yee of Caudex, funded by Bristol-Myers Squibb K.K.
KK, MH, KO, HH, KH, MM, SH, KO, CN, KS, SI, and NT participated in data acquisition. GK performed data analysis. GK, SGS, and MM contributed to the conception and design of the study. All authors participated in interpreting the data, critically reviewed the manuscript, and approved the final version for submission.
The study sponsor, Bristol-Myers Squibb K.K., provided the study drug and collaborated with the investigators to design the study and to collect and analyze the data. Editorial assistance from professional medical writers was funded by the sponsor.
Compliance with ethical standards
Conflict of interest
MH reports post-marketing surveillance study fees from Celgene, Fujifilm RI Pharma, and Shire Japan. K Ohta reports honoraria from Bristol-Myers Squibb K.K., Celgene K.K., Janssen Pharmaceutical K.K., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd, and Takeda Pharmaceutical Co. Ltd. HH reports research grants from Celgene, Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Sanofi, MSD, Kyowa Hakko Kirin, Chugai Pharmaceutical, Pfizer, Otsuka Pharmaceutical, and Ono Pharmaceutical, and honoraria from Celgene, Takeda Pharmaceutical, Daiichi Sankyo and Ono Pharmaceutical. KH reports honoraria from Bristol-Myers Squibb K.K., Ono Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd., Taiho Pharmaceutical, Johnson & Johnson, Celgene, AbbVie, Eisai, MSD, Kyowa Hakko Kirin, Novartis and Chugai Pharmaceutical, and consultancy from Otsuka Pharmaceutical and Meiji Seika Pharma. M Matsumoto reports honoraria from Janssen Pharmaceutical, Celgene, Takeda Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb K.K., Daiichi Sankyo, and Kyowa Hakko Kirin. SH reports a grant for investigator sponsored research from Bristol-Myers Squibb K.K. CN reports honoraria from Bristol-Myers Squibb K.K., Celgene K.K., Janssen Pharmaceutical K.K., Novartis Pharma K.K., and Takeda Pharmaceutical Co. Ltd, and research funding from Bristol-Myers Squibb K.K., Ono Pharmaceutical Co. Ltd, and Takeda Pharmaceutical Co. Ltd. KS reports personal fees from Celgene, Janssen Pharmaceutical, Takeda, Novartis, Bristol-Myers Squibb K.K., and Sanofi. SI reports honoraria from Bristol-Myers Squibb K.K., Celgene K.K., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co. Ltd, and Takeda Pharmaceutical Co. Ltd. GK and M Miyoshi report employment by Bristol-Myers Squibb K.K. SGS reports employment by and equity ownership in Bristol-Myers Squibb. K.K., K Ohashi, and NT declare no competing financial interests.
Data sharing statement
The Bristol-Myers Squibb policy on data sharing may be found at https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html.
- 3.National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Multiple Myeloma. Version 2.2020. 2019. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 30 Oct 2019.
- 7.Vij R, Chen C, Popov S, Durie B, Cook G, Zyczynski T, et al. Treatment patterns and associated outcomes in patients with relapsed or refractory multiple myeloma in the US and non-US countries: findings from PREAMBLE. Blood. 2017;130(suppl 1):3123.Google Scholar
- 14.Bristol-Myers Squibb, Princeton, NJ. Empliciti™ (elotuzumab) prescribing information. 2018. http://packageinserts.bms.com/pi/pi_empliciti.pdf. Accessed 24 Jan 2019.
- 15.European Medicines Agency, London, UK. Empliciti summary of product characteristics. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003967/WC500206673.pdf. Accessed 24 Jan 2019.
- 16.Japan Pharmaceuticals and Medical Devices Agency. New Drugs Approved in FY 2016. 2016. https://www.pmda.go.jp/files/000227116.pdf. Accessed 24 Jan 2019.
- 18.Weisel K, Dimopoulos MA, Lonial S, White D, Moreau P, Mateos MV, et al. Extended 5-y follow-up of phase 3 ELOQUENT-2 study: elotuzumab plus lenalidomide/dexamethasone vs lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. HemaSphere. 2018;2(suppl 1):590 (PS1298).Google Scholar
- 23.Dimopoulos M, Lonial S, Casado LF, Golightly M, Doyen C, Shelat S, et al. Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2015;15(suppl 3):e267–8.CrossRefGoogle Scholar
- 25.Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12):e516–27.CrossRefGoogle Scholar
- 29.Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–27.CrossRefGoogle Scholar
- 35.Dimopoulos MA, Mateos M-V, Cavo M, Suzuki K, Jakubowiak A, Knop S. One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (Pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): Alcyone. Blood. 2018;132(suppl 1):156.CrossRefGoogle Scholar
- 38.Kudo D, Ohashi K, Komeno T, Nakamura Y, Shinagawa A, Yoshida C, et al. Efficacy and safety of bortezomib-containing induction chemotherapy for autologous stem cell transplantation-eligible Japanese multiple myeloma patients: a phase 2 multicenter trial. Int J Myeloma. 2015;5(3):15–22.Google Scholar